PTC Therapeutics Inc.’s filing revealed that its Director SCHMERTZLER MICHAEL unloaded Company’s shares for reported $44860.0 on Jun 07. In the deal valued at $44.86 per share,1,000 shares were sold. As a result of this transaction, SCHMERTZLER MICHAEL now holds 116,766 shares worth roughly $ 4.68 million.
Then, Reeve Emma sold 2,652 shares, generating $157,885 in total proceeds. Upon selling the shares at $59.53, the Director now owns 7,200 shares.
Before that, Reeve Emma sold 7,116 shares. PTC Therapeutics Inc. shares valued at $423,630 were divested by the Director at a price of $59.53 per share. As a result of the transaction, Reeve Emma now holds 7,200 shares, worth roughly $0.29 million.
SVB Securities initiated its PTC Therapeutics Inc. [PTCT] rating to a Market perform in a research note published on Friday, March 17, 2023; the price target was $48. PT values the company’s stock at a premium of 16.5 to its Friday closing price.
Price Performance Review of PTCT
On Friday, PTC Therapeutics Inc. [NASDAQ:PTCT] saw its stock jump 1.47% to $40.08. On the same session, the stock had its day’s lowest price of $39.64, but rose to a high of $40.28. Over the last five days, the stock has gained 0.91%. PTC Therapeutics Inc. shares have risen nearly 5.00% since the year began. Nevertheless, the stocks have fallen -19.74% over the past one year. While a 52-week high of $59.84 was reached on 05/22/23, a 52-week low of $33.25 was recorded on 01/03/23. SMA at 50 days reached $40.14, while 200 days put it at $44.38. A total of 0.38 million shares were traded, compared to the trading of 0.35 million shares in the previous session.
Levels Of Support And Resistance For PTCT Stock
The 24-hour chart illustrates a support level at 39.72, which if violated will result in even more drops to 39.36. On the upside, there is a resistance level at 40.36. A further resistance level may holdings at 40.64. The Relative Strength Index (RSI) on the 14-day chart is 49.68, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.08, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 53.48%. Stochastics %K at 44.36% indicates the stock is a holding.
How much short interest is there in PTC Therapeutics Inc.?
A steep rise in short interest was recorded in PTC Therapeutics Inc. stocks on Aug 14, 2023, dropping by -0.25 million shares to a total of 7.21 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 7.46 million shares. There was a decline of -3.47%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 12.97% of the overall stock float, the days-to-cover ratio (short ratio) fell to 10.52.
PTC Therapeutics Inc. [PTCT] – Who Are The Largest Shareholders?
In filings from Fidelity Management & Research Co, it is revealed that the company now owns 8,807,011 shares, or roughly 11.87% of the outstanding PTCT shares. In other words, the investor’s shares have risen by 319,439 from its previous 13-F filing of 8487572.0. Additionally, The Vanguard Group, Inc. decreased -0.61% of its stake after which the total value it holdings stand at $297,226,935, while RTW Investments LP added 2.00% of its stake to hold $291.87 million in the firm. Over the last quarter, Wellington Management Co. LLP sold -211,327 shares of PTC Therapeutics Inc., while BlackRock Fund Advisors sold 161,904 shares. At present, Janus Henderson Investors US LLC is holding 3,566,593 shares valued at $143.88 million. Franklin Advisers, Inc. owned 3,295,210 shares of the company at the time of its most recent 13F filing, worth $132.93 million.
According to FactSet, PTC Therapeutics Inc.’s share price will average $52.13 in the next year, based on opinions of analysts polled by the firm. This is up nearly 24.05 percent from its previous closing price of $39.50. Analysts expect PTC Therapeutics Inc. stock to reach the higher price of $73.00, while the lowest price estimate is $35.00. However, 16 analysts have rated PTCT stock as an Overweight in their predictions for 2023.